Xing Liu

Xing Liu has extensive work experience in the field of molecular biology and drug discovery. From 2013 to 2018, they worked as an Associate Professor and Senior Engineer at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. In this role, they conducted research and contributed to scientific advancements.

In 2018, Liu joined Boston University as a Research Scientist. During their tenure, which lasted until 2022, they actively participated in research projects and collaborated with colleagues.

In 2022, Liu joined Seed Therapeutics as a Principal Scientist II. In this current role, they are responsible for the discovery and development of molecular glues for targeted protein degradation to treat cancer or other diseases. Xing leads and develops the in-house LumID platform-Photochemicalbiology for the identification of basal E3:POI interaction. Additionally, Liu develops TR-FRET assay for E3:POI PPI study and high-throughput screening for molecular glue, as well as cell-based drug screening assays for lead identification and optimization.

Xing Liu earned a Doctor of Philosophy (PhD) degree in Biochemistry/Proteomics from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This educational journey took place from 2008 to 2013.